New Tuberculosis Drug Study for Drug-Sensitive TB
Part of Infections, Lungs & breathing clinical trials.
This study tests a new tuberculosis drug called TBD09 combined with other TB medicines in people with newly diagnosed, drug-sensitive TB. The goal is to see if this combination works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years old
- Body weight between 35–100 kg (77–220 lbs)
- Newly diagnosed TB confirmed by lab test (Xpert MTB/RIF Ultra) showing the TB bacteria is sensitive to rifampicin
- Able to cough up sputum (phlegm) samples for testing
- No prior TB treatment in the last 60 days for this current TB episode
- No serious liver, kidney, or blood count problems; negative for hepatitis B and C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
This trial studies a treatment plan for people who have both drug-resistant tuberculosis (TB) and HIV. It focuses on starting a specific TB medication (bedaquiline) and, if needed, HIV treatment soon after enrollment to see what approach works best.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
Hear when a new Drug Susceptible Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.